Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.94
-0.32 (-1.75%)
Aug 27, 2025, 3:45 PM - Market open
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 27 analysts that cover Sarepta Therapeutics stock have a consensus rating of "Hold" and an average price target of $44.37, which forecasts a 147.32% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $170.
Price Target: $44.37 (+147.32%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 4 | 3 | 3 |
| Buy | 11 | 12 | 13 | 10 | 7 | 7 |
| Hold | 3 | 4 | 5 | 10 | 15 | 14 |
| Sell | 0 | 0 | 0 | 0 | 2 | 2 |
| Strong Sell | 2 | 1 | 0 | 1 | 2 | 4 |
| Total | 21 | 22 | 24 | 25 | 29 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -72.13% | Aug 25, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $17 → $16 | Sell | Maintains | $17 → $16 | -10.81% | Aug 21, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $10 → $17 | Sell | Maintains | $10 → $17 | -5.24% | Aug 20, 2025 |
| Deutsche Bank | Deutsche Bank | Strong Sell Maintains $6 → $12 | Strong Sell | Maintains | $6 → $12 | -33.11% | Aug 15, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $10 → $19 | Hold | Maintains | $10 → $19 | +5.91% | Aug 7, 2025 |
Financial Forecast
Revenue This Year
2.08B
from 1.90B
Increased by 9.41%
Revenue Next Year
1.60B
from 2.08B
Decreased by -23.26%
EPS This Year
-4.77
from 2.34
EPS Next Year
1.96
from -4.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.4B | 2.4B | |||
| Avg | 2.1B | 1.6B | |||
| Low | 1.6B | 944.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 13.6% | |||
| Avg | 9.4% | -23.3% | |||
| Low | -16.3% | -54.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.58 | 6.90 | |||
| Avg | -4.77 | 1.96 | |||
| Low | -7.02 | -2.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.